FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Fluicell AB's Free Cash Flow for the
three
months ended in Mar. 2026 was kr-0.98 Mil. Fluicell AB's Revenue for the
three
months ended in Mar. 2026 was kr6.09 Mil. Therefore, Fluicell AB's FCF Margin % for the quarter that ended in Mar. 2026 was -16.15%.
The historical rank and industry rank for Fluicell AB's FCF Margin % or its related term are showing as below:
OSTO:FLUI'
s FCF Margin % Range Over the Past 10 Years
Min: -1143.47 Med: -732.37 Max: -71.06
Current: -71.06
During the past 11 years, the highest FCF Margin % of Fluicell AB was -71.06%. The lowest was -1143.47%. And the median was -732.37%.
OSTO:FLUI's FCF Margin % is ranked better than 51.67% of 956
companies
in the Biotechnology industry
Industry Median: -85.21
vs OSTO:FLUI: -71.06
Fluicell AB FCF Margin % Related Terms
Fluicell AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for Fluicell AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:FLUI vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Fluicell AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Fluicell AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fluicell AB (OSTO:FLUI) has a FCF Margin % of -16.15% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fluicell AB and its competitors. According to the industry distribution chart, Fluicell AB ranks #462 out of 956 companies in the Biotechnology industry, placing it in the top 48.3%.
Is Fluicell AB's FCF Margin % too high?
Fluicell AB's current FCF Margin % is -16.15%. Based on the distribution chart, Fluicell AB ranks #462 out of 956 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fluicell AB has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #462 out of 956 companies for FCF Margin %. This puts Fluicell AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Fluicell AB and its competitors. Fluicell AB's current FCF Margin % is -16.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Modestly Undervalued. The stock's GF Value™ is kr34.58, compared to a current price of kr30.90 — trading 10.6% below its estimated fair value. The current FCF Margin % is -16.15%. Fluicell AB's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current FCF Margin % is -16.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of kr30.90 is trading 10.6% below its estimated GF Value™ of kr34.58.
GuruFocus considers Fluicell AB to be Modestly Undervalued.
Key valuation signals for OSTO:FLUI:
FCF Margin %: -16.15%
GF Value™: kr34.58 vs. price of kr30.90 (10.6% below fair value)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
54GF Score
Get the complete analysis for OSTO:FLUI
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
